Expertise in
49
conditions

Dr. Ivor J. Percent

Hematology | Oncology
22395 Edgewater Dr, 
Port Charlotte, FL 
Accepting New Patients
Offers Telehealth
Expertise in
49
conditions
22395 Edgewater Dr, 
Port Charlotte, FL 

Overview

Ivor Percent is a Hematologist and an Oncologist practicing medicine in Port Charlotte, Florida.

Dr. Percent is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Myelodysplastic Syndrome (MDS), and Urothelial Cancer.

Dr. Percent is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 7 clinical trials. Dr. Percent is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Alabama at Birmingham , Internal Medicine

Hospital Affiliations

Adventhealth Port Charlotte
Sarasota Memorial Hospital
Sarasota Memorial Hospital - Venice
Desoto Memorial Hospital
Hca Florida Fawcett Hospital
Fawcett Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Florida Cancer Specialists Pl
22395 Edgewater Dr, Port Charlotte, FL 33980

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Biological
Study Drugs: CAB-AXL-ADC, PD-1 Inhibitor
Study Phase: Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

12 Total Publications

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
Journal: Nature medicine
Published: October 15, 2025
Similar Doctors
Expertise in
54
conditions
Dr. Christopher F. Lobo
Hematology | Oncology
Expertise in
54
conditions
Dr. Christopher F. Lobo
Hematology | Oncology
Referral may be required

Florida Cancer Specialists Pl

22395 Edgewater Dr, 
Port Charlotte, FL 
 (0.1 miles away)
941-766-7222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Lobo is a Hematologist and an Oncologist practicing medicine in Port Charlotte, Florida. Dr. Lobo is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Cryoglobulinemia, and Familial Mixed Cryoglobulinemia. Dr. Lobo is board certified in American Board Of Internal Medicine. Dr. Lobo is currently accepting new patients.

Expertise in
32
conditions
Dr. Lowell L. Hart
Hematology | Oncology
Expertise in
32
conditions
Dr. Lowell L. Hart
Hematology | Oncology
Referral may be required

Florida Cancer Specialists Pl

8260 Gladiolus Dr, 
Fort Myers, FL 
 (32.6 miles away)
239-437-5755
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lowell Hart is a Hematologist and an Oncologist practicing medicine in Fort Myers, Florida. Dr. Hart is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Hart is board certified in American Board Of Internal Medicine. Dr. Hart is currently accepting new patients.

Expertise in
21
conditions
Dr. William N. Harwin
Hematology | Oncology
Expertise in
21
conditions
Dr. William N. Harwin
Hematology | Oncology
Referral may be required

Florida Cancer Specialists P L

15681 New Hampshire Ct, 
Fort Myers, FL 
 (33.0 miles away)
239-437-4444
Languages Spoken:
English
See accepted insurances

William Harwin is a Hematologist and an Oncologist practicing medicine in Fort Myers, Florida. Dr. Harwin is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Clear Cell Sarcoma.

Frequently Asked Questions about Dr. Ivor J. Percent

How do I make an appointment with Dr. Ivor J. Percent?

You can book an appointment with Dr. Ivor J. Percent by calling their office at 941-766-7222. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ivor J. Percent a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ivor J. Percent is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ivor J. Percent specialize in?

While Dr. Ivor J. Percent is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ivor J. Percent participate in research or clinical trials?

Yes. Dr. Ivor J. Percent has published 12 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Ivor J. Percent's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ivor J. Percent accept my insurance?

Dr. Ivor J. Percent accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 941-766-7222 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Percent's expertise for a condition
ConditionClose
    View All 45 Advanced Conditions
    View All 97 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile